Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/5d/2a/05/5d2a05d6-9e8f-ebde-5b02-4e7f17c31d76/mza_720905515349598464.jpg/600x600bb.jpg

Foundation Fighting Blindness

238 episodes

1 week ago

The Foundation funded preclinical studies for the approach and launched Opus.

All content for Foundation Fighting Blindness is the property of Foundation Fighting Blindness and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

The Foundation funded preclinical studies for the approach and launched Opus.

Science

https://i1.sndcdn.com/avatars-YaeofrSuCwcgCMse-dnoERw-original.jpg

Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial

Foundation Fighting Blindness

3 minutes 37 seconds

2 months ago

Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial

NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.